Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | PPM1B | O75688 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189191 | 1.00 | TSHR (0.45) | TSHRHSP90B1LMNAPPM1BPTPN1 | |
| SCHEMBL28833013 | 0.98 | TSHR (0.44) | TSHRHSP90B1LMNAPPM1BPTPN1 | |
| SCHEMBL29981924 | 0.98 | TSHR (0.46) | TSHRHSP90B1LMNAPPM1BPTPN1 | |
| SCHEMBL6666772 | 0.85 | PPM1B (0.41) | TSHRHSP90B1PPM1BPTPN1PPP1CC | |
| SCHEMBL28475631 | 0.82 | LGALS3 (0.33) | — | |
| SCHEMBL27766467 | 0.82 | AHCY (0.45) | TSHRLMNAPPM1BPTPN1PPP1CC | |
| SCHEMBL14317077 | 0.82 | AHCY (0.45) | TSHRLMNAPPM1BPTPN1PPP1CC | |
| SCHEMBL27737603 | 0.81 | LGALS3 (0.46) | TSHRHSP90B1LMNAPPM1BPTPN1 | |
| SCHEMBL28214269 | 0.81 | AHCY (0.34) | HSP90B1 | |
| SCHEMBL19226382 | 0.80 | TSHR (0.41) | TSHRHSP90B1PPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343285-B1 | Peptoid compounds useful as antibiotics | UNIV WOLLONGONG (AU) | 2015-02-25 | — | — | EP | disclosed |
| US-20120108499-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2012-05-03 | — | — | US | disclosed |
| EP-2343285-A2 | Peptoid compounds | UNIVERSITY OF WOLLONGONG (AU) | 2011-07-13 | — | — | EP | disclosed |
| US-20100167995-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2010-07-01 | — | — | US | disclosed |
| US-7612036-B2 | Peptoid compounds | UNIVERSITY OF WOLLONGONG (AU) | 2009-11-03 | — | — | US | disclosed |
| EP-1412336-A4 | PEPTOID COMPOUNDS | UNIV WOLLONGONG (AU) | 2007-08-29 | — | — | EP | disclosed |
| US-20070111927-A1 | Peptoid compounds | UNIVERSITY OF WOLLONGONG (AU) | 2007-05-17 | — | — | US | disclosed |
| US-7160854-B2 | Binaphthyl peptidomimetics for treating vancomycin resistant Staphylococcus aureas infections | UNIVERSITY OF WOLLONGONG (AU) | 2007-01-09 | — | — | US | disclosed |
| US-20050043509-A1 | Peptoid compounds | UNIVERSITY OF WOLLONGONG | 2005-02-24 | — | — | US | disclosed |
| EP-1358255-A4 | POROUS POLYMERS | BIO LAYER PTY LTD (AU) | 2004-11-10 | — | — | EP | disclosed |
| US-20040138323-A1 | Porous polymers | BIO-LAYER PTY. LIMITED (AU) | 2004-07-15 | — | — | US | disclosed |
| EP-1412336-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2004-04-28 | — | — | EP | disclosed |
| EP-1358255-A1 | POROUS POLYMERS | Polymerat Pty Ltd (AU) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003040218-A1 | POROUS POLYMER FILMS | POLYMERAT PTY LTD (AU) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003002545-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2003-01-09 | — | — | WO | disclosed |
| WO-2002050174-A1 | POROUS POLYMERS | POLYMERAT PTY LTD (AU) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108499-A1 | PEPTOID COMPOUNDS | VIP, FPR1, VIPR1 | TSHR 4240/4885HSP90B1 96/4885LMNA 4362/4885 |
| US-20100167995-A1 | PEPTOID COMPOUNDS | VIP, FPR1, VIPR1 | TSHR 4240/4885HSP90B1 96/4885LMNA 4362/4885 |
| US-20070111927-A1 | Peptoid compounds | VIP, FPR1, VIPR1 | TSHR 4240/4885HSP90B1 96/4885LMNA 4362/4885 |
| US-20050043509-A1 | Peptoid compounds | VIP, FPR1, VIPR1 | TSHR 4240/4885HSP90B1 96/4885LMNA 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.